This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Meglumine antimoniate
- DrugBank Accession Number
- DB13732
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental, Investigational
- Structure
Structure for Meglumine antimoniate (DB13732)
- Weight
- Average: 365.98
Monoisotopic: 365.00705 - Chemical Formula
- C7H18NO8Sb
- Synonyms
- Antimoniato de meglumina
- Glucantim
- Glucantime
- Meglumine antimonate
- Meglumine antimoniate
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
Categories
- ATC Codes
- P01CB01 — Meglumine antimonate
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as hexoses. These are monosaccharides in which the sugar unit is a is a six-carbon containing moeity.
- Kingdom
- Organic compounds
- Super Class
- Organic oxygen compounds
- Class
- Organooxygen compounds
- Sub Class
- Carbohydrates and carbohydrate conjugates
- Direct Parent
- Hexoses
- Alternative Parents
- Organic antimonates / 1,3-aminoalcohols / Secondary alcohols / Organic antimony salts / 1,2-aminoalcohols / Polyols / Dialkylamines / Primary alcohols / Organopnictogen compounds / Organic oxides show 1 more
- Substituents
- 1,2-aminoalcohol / 1,3-aminoalcohol / Alcohol / Aliphatic acyclic compound / Amine / Hexose monosaccharide / Hydrocarbon derivative / Organic antimonate / Organic antimony salt / Organic metal salt show 11 more
- Molecular Framework
- Aliphatic acyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 75G4TW236W
- CAS number
- 133-51-7
- InChI Key
- XOGYVDXPYVPAAQ-SESJOKTNSA-M
- InChI
- InChI=1S/C7H17NO5.H2O.2O.Sb/c1-8-2-4(10)6(12)7(13)5(11)3-9;;;;/h4-13H,2-3H2,1H3;1H2;;;/q;;;;+1/p-1/t4-,5+,6+,7+;;;;/m0..../s1
- IUPAC Name
- (2R,3R,4R,5S)-6-(methylamino)hexane-1,2,3,4,5-pentol; oxostibinic acid
- SMILES
- O[Sb](=O)=O.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO
References
- General References
- Not Available
- External Links
- ChemSpider
- 58479
- 319866
- ChEMBL
- CHEMBL239129
- Wikipedia
- Meglumine_antimoniate
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count 4 Completed Treatment Cutaneous Leishmaniasis 1 4 Completed Treatment Localized Cutaneous Leishmaniasis 1 4 Completed Treatment Visceral Leishmaniasis 1 4 Terminated Treatment Visceral Leishmaniasis 1 3 Active Not Recruiting Treatment Cutaneous Leishmaniases 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Solution Parenteral 1.5 g Injection, solution Intramuscular Solution Intramuscular 1.5 g Solution Intramuscular 150000 g - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 240.0 mg/mL ALOGPS logP -2.4 ALOGPS logP -3.4 Chemaxon logS 0.09 ALOGPS pKa (Strongest Acidic) 12.65 Chemaxon pKa (Strongest Basic) 9.11 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 6 Chemaxon Hydrogen Donor Count 6 Chemaxon Polar Surface Area 113.18 Å2 Chemaxon Rotatable Bond Count 6 Chemaxon Refractivity 44.84 m3·mol-1 Chemaxon Polarizability 19.52 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 1 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Drug created at June 23, 2017 20:47 / Updated at December 02, 2020 11:50